FDA Brief

Warning letters Drugs

FDA warning letter to

Mark S. Dacey, M.D.

High riskIssued Feb 2Posted Feb 10Center for Drug Evaluation and Research (CDER)

FDA warns Dr. Mark S. Dacey that a trial subject underwent an optional eye-fluid sampling procedure after twice declining consent.

What happened

FDA inspected Dr. Dacey’s clinical site from October 23 to November 8, 2024, under its Bioresearch Monitoring Program. FDA found that a subject underwent collection of aqueous humor from the study eye on March 5, 2024, even though the subject had declined consent on September 26 and October 18, 2023, for optional sample collection. FDA also found the December 3, 2024, response inadequate because it lacked details on oversight and training for the planned corrective actions.

What FDA found

  1. The investigator did not obtain legally effective informed consent before a subject took part in research.

    21 CFR 50.20; 21 CFR 312.60
  2. A subject underwent collection of aqueous humor from the study eye even though the subject had declined consent for optional sample collection twice.

    21 CFR 50.20; protocol requirement for signed consent
  3. The investigator’s written response did not give enough detail on how consent oversight, source-binder labeling, CTMS notation, and staff training would be implemented.

What FDA wants

FDA asks Dr. Dacey to notify the office in writing within 15 business days of receipt of the letter of actions taken to prevent similar violations. Failure to address the matter adequately may lead to regulatory action.

Who should pay attention

  • clinical investigators and research staff
  • research sites and ethics boards
  • sponsors relying on site consent checks

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  2. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  3. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  4. Sourav K. Mishra, M.D. / All India Institute of Medical Sciences

    FDA warned clinical investigator Dr. Sourav K. Mishra at AIIMS Bhubaneswar over a doxorubicin liposome bioequivalence study that broke protocol and consent rules.

    High risk